Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Randomized Phase II Study of consecutive-day versus alternate-day treatment with S-1 as Second-line chemotherapy in advanced pancreatic cancer.

Trial Profile

Multicenter Randomized Phase II Study of consecutive-day versus alternate-day treatment with S-1 as Second-line chemotherapy in advanced pancreatic cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms SCOTCH
  • Most Recent Events

    • 31 Oct 2017 Status changed from recruiting to completed.
    • 06 Jan 2015 Planned End Date changed from 1 Dec 2015 to 31 Dec 2016 as reported by the University Hospital Medical Information Network record.
    • 22 Jan 2014 Status changed from not yet recruiting to recruiting as reported by the University Hospital Medical Information Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top